Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlansoprazole IV PK/PD in Healthy Chinese Adults
NCT03120273Phase 1Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dexlansoprazole in gastroesophageal reflux disease (GERD) (5 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Percentage time with the intragastric potential of hydrogen (pH)>4, Percentage time with the intragastric pH>6 and 2 more. Status: unknown.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03120273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03120273.